Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2006 2
2008 1
2009 1
2014 1
2016 1
2017 1
2018 2
2019 1
2021 1
2022 1
2023 2
2024 1
2025 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
PARP-1 as a novel target in endocrine-resistant breast cancer.
Zicarelli A, Talia M, Lainé M, Lappano R, Maggiolini M, Greene GL. Zicarelli A, et al. Among authors: laine m. J Exp Clin Cancer Res. 2025 Jun 16;44(1):175. doi: 10.1186/s13046-025-03441-4. J Exp Clin Cancer Res. 2025. PMID: 40518539 Free PMC article.
Dynamic epi-transcriptomic landscape mapping with disease progression in estrogen receptor-positive breast cancer.
Keelan S, Ola M, Charmsaz S, Cocchiglia S, Ottaviani D, Hickey S, Purcell S, Bane F, Hegarty A, Doherty B, Sheehan K, Hudson L, Cosgrove N, Roux B, Laine M, Greene G, Varešlija D, Hill AK, Young L. Keelan S, et al. Among authors: laine m. Cancer Commun (Lond). 2023 May;43(5):615-619. doi: 10.1002/cac2.12407. Epub 2023 Jan 20. Cancer Commun (Lond). 2023. PMID: 36670046 Free PMC article. No abstract available.
The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells.
Fanning SW, Jeselsohn R, Dharmarajan V, Mayne CG, Karimi M, Buchwalter G, Houtman R, Toy W, Fowler CE, Han R, Lainé M, Carlson KE, Martin TA, Nowak J, Nwachukwu JC, Hosfield DJ, Chandarlapaty S, Tajkhorshid E, Nettles KW, Griffin PR, Shen Y, Katzenellenbogen JA, Brown M, Greene GL. Fanning SW, et al. Among authors: laine m. Elife. 2018 Nov 29;7:e37161. doi: 10.7554/eLife.37161. Elife. 2018. PMID: 30489256 Free PMC article.
The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer.
Cocce KJ, Jasper JS, Desautels TK, Everett L, Wardell S, Westerling T, Baldi R, Wright TM, Tavares K, Yllanes A, Bae Y, Blitzer JT, Logsdon C, Rakiec DP, Ruddy DA, Jiang T, Broadwater G, Hyslop T, Hall A, Laine M, Phung L, Greene GL, Martin LA, Pancholi S, Dowsett M, Detre S, Marks JR, Crawford GE, Brown M, Norris JD, Chang CY, McDonnell DP. Cocce KJ, et al. Among authors: laine m. Cell Rep. 2019 Oct 22;29(4):889-903.e10. doi: 10.1016/j.celrep.2019.09.032. Cell Rep. 2019. PMID: 31644911 Free PMC article.
Progesterone receptor isoforms, agonists and antagonists differentially reprogram estrogen signaling.
Singhal H, Greene ME, Zarnke AL, Laine M, Al Abosy R, Chang YF, Dembo AG, Schoenfelt K, Vadhi R, Qiu X, Rao P, Santhamma B, Nair HB, Nickisch KJ, Long HW, Becker L, Brown M, Greene GL. Singhal H, et al. Among authors: laine m. Oncotarget. 2017 Sep 28;9(4):4282-4300. doi: 10.18632/oncotarget.21378. eCollection 2018 Jan 12. Oncotarget. 2017. PMID: 29435103 Free PMC article.
17 results